{"id":50151,"date":"2025-12-08T20:38:26","date_gmt":"2025-12-08T12:38:26","guid":{"rendered":"https:\/\/flcube.com\/?p=50151"},"modified":"2025-12-08T20:38:27","modified_gmt":"2025-12-08T12:38:27","slug":"otr-therapeutics-series-a-raises-100m-for-neurology-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50151","title":{"rendered":"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline"},"content":{"rendered":"\n<p><strong>OTR Therapeutics Limited<\/strong> announced the successful completion of a <strong>USD 100 million Series A financing<\/strong>, backed by <strong>True Light Capital<\/strong> (Temasek subsidiary), <strong>LAV<\/strong>, <strong>Pfizer Ventures<\/strong>, and <strong>Sirona Capital<\/strong>. The company, founded in March 2025, will advance its pipeline across immunology, inflammation, and oncology while expanding its R&amp;D hub and acquiring a preclinical neurology program.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-summary-amp-investor-syndicate\">Financing Summary &amp; Investor Syndicate<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Round<\/th><th>Amount<\/th><th>Lead Investors<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Series A<\/strong><\/td><td>USD\u202f100\u202fmillion<\/td><td>True Light Capital (Temasek), LAV, Pfizer Ventures, Sirona Capital<\/td><td>Platform expansion + pipeline advancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-business-model\">Company Profile &amp; Business Model<\/h2>\n\n\n\n<p><strong>Founded<\/strong>: March\u202f2025<br><strong>Model<\/strong>: Novel, scalable, capital-efficient approach synergizing <strong>internal R&amp;D<\/strong> with <strong>strategic curation of external innovation<\/strong><\/p>\n\n\n\n<p><strong>Core Capabilities:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Scientific excellence with operational agility<\/li>\n\n\n\n<li>Deep regional insights leveraging China\u2019s development ecosystem<\/li>\n\n\n\n<li>Focus on high-impact therapies with expedited development pathways<\/li>\n<\/ul>\n\n\n\n<p><strong>Pipeline Focus<\/strong>: Immunology &amp; inflammation, oncology, and other disease areas with significant treatment gaps<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-use-of-proceeds\">Use of Proceeds<\/h2>\n\n\n\n<p><strong>80% Pipeline Advancement:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Advance differentiated programs through clinical development<\/li>\n\n\n\n<li>Support both proprietary discovery and acquired assets<\/li>\n<\/ul>\n\n\n\n<p><strong>20% R&amp;D Hub Expansion:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Build laboratory and clinical development infrastructure<\/li>\n\n\n\n<li>Enhance strategic partnership capabilities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-acquisition-neurology-program\">Strategic Acquisition: Neurology Program<\/h2>\n\n\n\n<p><strong>Asset Acquired<\/strong>: Preclinical program with <strong>best-in-class potential<\/strong> for neurological diseases with high unmet needs<\/p>\n\n\n\n<p><strong>Strategic Fit:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Expands pipeline beyond core I&amp;I and oncology focus<\/li>\n\n\n\n<li>Aligns with strategy to identify and advance promising early-stage assets<\/li>\n\n\n\n<li>Positions OTR for global clinical development in underserved CNS indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-position\">Market Context &amp; Competitive Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Biotech Investment<\/strong>: $100M Series A represents substantial early-stage financing, signaling strong investor confidence<\/li>\n\n\n\n<li><strong>Platform Differentiation<\/strong>: Hybrid internal\/external model reduces R&amp;D risk while maintaining innovation control<\/li>\n\n\n\n<li><strong>Neurology Opportunity<\/strong>: CNS diseases represent $150 billion global market with limited treatment options<\/li>\n\n\n\n<li><strong>Investor Validation<\/strong>: Pfizer Ventures and Temasek backing provides strategic credibility and potential partnership pathways<\/li>\n\n\n\n<li><strong>Timeline<\/strong>: First IND filings expected 2026-2027 across multiple programs<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding OTR Therapeutics&#8217; pipeline development, acquisition integration, and market strategy. Actual results may differ due to clinical outcomes, regulatory processes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50155,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,4490],"class_list":["post-50151","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-otr-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>OTR Therapeutics Series-A Raises $100M for Neurology Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing, backed by True Light Capital (Temasek subsidiary), LAV, Pfizer Ventures, and Sirona Capital. The company, founded in March 2025, will advance its pipeline across immunology, inflammation, and oncology while expanding its R&amp;D hub and acquiring a preclinical neurology program.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50151\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline\" \/>\n<meta property=\"og:description\" content=\"OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing, backed by True Light Capital (Temasek subsidiary), LAV, Pfizer Ventures, and Sirona Capital. The company, founded in March 2025, will advance its pipeline across immunology, inflammation, and oncology while expanding its R&amp;D hub and acquiring a preclinical neurology program.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50151\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T12:38:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T12:38:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50151#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50151\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline\",\"datePublished\":\"2025-12-08T12:38:26+00:00\",\"dateModified\":\"2025-12-08T12:38:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50151\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50151#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0801.webp\",\"keywords\":[\"Biotech\",\"Finance\",\"OTR Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50151#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50151\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50151\",\"name\":\"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50151#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50151#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0801.webp\",\"datePublished\":\"2025-12-08T12:38:26+00:00\",\"dateModified\":\"2025-12-08T12:38:27+00:00\",\"description\":\"OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing, backed by True Light Capital (Temasek subsidiary), LAV, Pfizer Ventures, and Sirona Capital. The company, founded in March 2025, will advance its pipeline across immunology, inflammation, and oncology while expanding its R&D hub and acquiring a preclinical neurology program.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50151#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50151\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50151#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0801.webp\",\"width\":1080,\"height\":608,\"caption\":\"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50151#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing, backed by True Light Capital (Temasek subsidiary), LAV, Pfizer Ventures, and Sirona Capital. The company, founded in March 2025, will advance its pipeline across immunology, inflammation, and oncology while expanding its R&D hub and acquiring a preclinical neurology program.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50151","og_locale":"en_US","og_type":"article","og_title":"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline","og_description":"OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing, backed by True Light Capital (Temasek subsidiary), LAV, Pfizer Ventures, and Sirona Capital. The company, founded in March 2025, will advance its pipeline across immunology, inflammation, and oncology while expanding its R&D hub and acquiring a preclinical neurology program.","og_url":"https:\/\/flcube.com\/?p=50151","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-08T12:38:26+00:00","article_modified_time":"2025-12-08T12:38:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50151#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50151"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline","datePublished":"2025-12-08T12:38:26+00:00","dateModified":"2025-12-08T12:38:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50151"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50151#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0801.webp","keywords":["Biotech","Finance","OTR Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50151#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50151","url":"https:\/\/flcube.com\/?p=50151","name":"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50151#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50151#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0801.webp","datePublished":"2025-12-08T12:38:26+00:00","dateModified":"2025-12-08T12:38:27+00:00","description":"OTR Therapeutics Limited announced the successful completion of a USD 100 million Series A financing, backed by True Light Capital (Temasek subsidiary), LAV, Pfizer Ventures, and Sirona Capital. The company, founded in March 2025, will advance its pipeline across immunology, inflammation, and oncology while expanding its R&D hub and acquiring a preclinical neurology program.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50151#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50151"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50151#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0801.webp","width":1080,"height":608,"caption":"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50151#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"OTR Therapeutics Series-A Raises $100M for Neurology Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0801.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50151"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50151\/revisions"}],"predecessor-version":[{"id":50156,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50151\/revisions\/50156"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50155"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}